Pablo Tebas

19.9k total citations · 3 hit papers
214 papers, 10.6k citations indexed

About

Pablo Tebas is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Pablo Tebas has authored 214 papers receiving a total of 10.6k indexed citations (citations by other indexed papers that have themselves been cited), including 130 papers in Infectious Diseases, 113 papers in Virology and 87 papers in Emergency Medicine. Recurrent topics in Pablo Tebas's work include HIV Research and Treatment (111 papers), HIV/AIDS drug development and treatment (99 papers) and HIV-related health complications and treatments (87 papers). Pablo Tebas is often cited by papers focused on HIV Research and Treatment (111 papers), HIV/AIDS drug development and treatment (99 papers) and HIV-related health complications and treatments (87 papers). Pablo Tebas collaborates with scholars based in United States, United Kingdom and Italy. Pablo Tebas's co-authors include William G. Powderly, Kevin E. Yarasheski, Grace A. McComsey, Sherry Claxton, Kristin Mondy, Ian Frank, Woraphot Tantisiriwat, Roger Bedimo, Henning Drechsler and Edgar T. Overton and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Pablo Tebas

209 papers receiving 10.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV

2014 973 citations Pablo Tebas, Ian Frank et al. profile →
Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

2011 381 citations Eric S. Daar, Camlin Tierney et al. The Journal of Infectious Diseases profile →
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

2017 257 citations Pablo Tebas, Eric S. Daar et al. profile →

Peers

Countries citing papers authored by Pablo Tebas

Since Specialization

Citations

This map shows the geographic impact of Pablo Tebas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pablo Tebas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pablo Tebas more than expected).

Fields of papers citing papers by Pablo Tebas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pablo Tebas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pablo Tebas. The network helps show where Pablo Tebas may publish in the future.

Co-authorship network of co-authors of Pablo Tebas

This figure shows the co-authorship network connecting the top 25 collaborators of Pablo Tebas. A scholar is included among the top collaborators of Pablo Tebas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pablo Tebas. Pablo Tebas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Factors associated with resistance of HIV-1 reservoir viruses to neutralization by autologous IgG antibodies 2025 ·Journal of Clinical Investigation ·(unknown), Joseph Varriale, (unknown), (unknown), (unknown), Toong Seng Tan, Jun Lai, (unknown), Kenneth Lynn, Karam Mounzer, Pablo Tebas, Luis J. Montaner, Rebecca Hoh, Xu G. Yu, Mathias Lichterfeld, Francesco R. Simonetti, Colin Kovacs, Steven G. Deeks, Janet D. Siliciano, Robert F. Siliciano	0
2	Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial 2024 ·The Lancet HIV ·Jean‐Michel Molina, Giuliano Rizzardini, Catherine Orrell, (unknown), Alexandra Calmy, Shinichi Oka, Federico Hinestrosa, (unknown), Pablo Tebas, Sharon Walmsley, Anjana Grandhi, Stephanie O. Klopfer, Isaias Noel Gendrano, Karen Eves, (unknown), (unknown), Jason Kim	10
3	Combination of Extended Antivirals With Antiretrovirals for Severe Mpox in Advanced Human Immunodeficiency Virus Infection: Case Series of 4 Patients 2024 ·Open Forum Infectious Diseases ·Michael Tran Duong, Pablo Tebas, (unknown), (unknown), (unknown), Stuart N. Isaacs, Zsofia Szep	3
4	Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells 2024 ·Nature Immunology ·(unknown), (unknown), Fengting Wu, (unknown), (unknown), Srona Sengupta, (unknown), Francesco R. Simonetti, Jun Lai, Pablo Tebas, Kenneth Lynn, Rebecca Hoh, Steven G. Deeks, Janet D. Siliciano, Luis J. Montaner, Robert F. Siliciano	17
5	Cognate antigen engagement induces HIV-1 expression in latently infected CD4+ T cells from people on long-term antiretroviral therapy 2024 ·Immunity ·(unknown), Filippo Dragoni, (unknown), Fengting Wu, Jun Lai, Hao Zhang, James R. White, Rebecca Hoh, Kenneth Lynn, Pablo Tebas, Karam Mounzer, Steven G. Deeks, Luis J. Montaner, Janet D. Siliciano, Robert F. Siliciano, Francesco R. Simonetti	1
6	Evaluation and Real-world Experience of a Neutralization Susceptibility Screening Assay for Broadly Neutralizing Anti–HIV-1 Antibodies 2024 ·The Journal of Infectious Diseases ·Marie H. Pahus, Yu Zheng, (unknown), Jesper Damsgaard Gunst, Pablo Tebas, Babafemi Taiwo, Ole S. Søgaard, Michael J. Peluso, Yolanda Lie, Jacqueline D. Reeves, Christos J. Petropoulos, Marina Caskey, Katharine J. Bar	2
7	Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States 2023 ·SHILAP Revista de lepidopterología ·Andrea Bilger, (unknown), Frances K. Barg, Katharine A. Rendle, (unknown), (unknown), Nora L. Jones, (unknown), John A. Sauceda, Pablo Tebas, Karam Mounzer, David S. Metzger, Luis J. Montaner, Karine Dubé	12
8	Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy 2022 ·Cell Reports Medicine ·Jonathan D. Herman, Chuangqi Wang, John S. Burke, (unknown), (unknown), Jaewon Kang, (unknown), (unknown), Sally Shin, Ian Frank, Don L. Siegel, Pablo Tebas, Grace Choi, Pamela A. Shaw, Hyunah Yoon, Liise-anne Pirofski, Boris Jülg, Katharine J. Bar, Douglas A. Lauffenburger, Galit Alter	17
9	Unraveling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2 2022 ·Open Forum Infectious Diseases ·Jonathan Fintzi, Tyler Bonnett, Pablo Tebas, Vincent C. Marconi, Corri B. Levine, Hana M. El Sahly, Susan McLellan, Constance A. Benson, Christina A. Rostad, Anuradha Ganesan, Nikhil Huprikar, Maria G. Frank, Richard A. Mularski, Robert L. Atmar, Pauline K. Park, William R. Short, John H. Beigel, Aneesh K. Mehta, Daniel A. Sweeney	2
10	Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV 2021 ·Nature Communications ·Leila B. Giron, Clovis S. Palmer, Qin Liu, Xiangfan Yin, Emmanouil Papasavvas, Radwa Sharaf, Behzad Etemad, Mohammad Damra, Aaron R. Goldman, Hsin‐Yao Tang, Rowena Johnston, Karam Mounzer, Jay R. Kostman, Pablo Tebas, Alan Landay, Luis J. Montaner, Jeffrey M. Jacobson, Jonathan Z. Li, Mohamed Abdel‐Mohsen	37
11	Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19 2021 ·Annals of Internal Medicine ·Safia Kuriakose, (unknown), Alice K. Pau, Eric S. Daar, Rajesh T. Gandhi, Pablo Tebas, Laura Evans, Roy M. Gulick, H. Clifford Lane, Henry Masur	13
12	Deconstructing the Treatment Effect of Remdesivir in the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1: Implications for Critical Care Resource Utilization 2021 ·Clinical Infectious Diseases ·Jonathan Fintzi, Tyler Bonnett, Daniel A. Sweeney, Nikhil Huprikar, Anuradha Ganesan, Maria G. Frank, Susan McLellan, Lori E. Dodd, Pablo Tebas, Aneesh K. Mehta	11
13	SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients 2020 ·Journal of Clinical Microbiology ·Susanne N. Walker, Neethu Chokkalingam, Emma L. Reuschel, Mansi Purwar, Ziyang Xu, E. Gary, Kevin Y. Kim, (unknown), Katherine Schultheis, Jewell Walters, Stephanie Ramos, Kar Muthumani, Trevor R.F. Smith, Kate E. Broderick, Pablo Tebas, Ami Patel, David B. Weiner, Daniel W. Kulp	42
14	Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1 2020 ·Proceedings of the National Academy of Sciences ·Lynn N. Bertagnolli, Joseph Varriale, (unknown), (unknown), Francesco R. Simonetti, Jennifer A. White, Subul Beg, Kenneth Lynn, Karam Mounzer, Ian Frank, Pablo Tebas, Katharine J. Bar, Luis J. Montaner, Robert F. Siliciano, Janet D. Siliciano	46
15	Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial 2020 ·AIDS Research and Human Retroviruses ·Emmanouil Papasavvas, Livio Azzoni, Amélie Pagliuzza, Mohamed Abdel‐Mohsen, Brian N. Ross, (unknown), Bonnie J. Howell, Daria J. Hazuda, Nicolas Chomont, Qingsheng Li, Karam Mounzer, Jay R. Kostman, Pablo Tebas, Luis J. Montaner	8
16	Successive annual influenza vaccination induces a recurrent oligoclonotypic memory response in circulating T follicular helper cells 2017 ·Science Immunology ·Ramin S. Herati, Alexander Muselman, Laura A. Vella, Bertram Bengsch, Kaela Parkhouse, (unknown), Jonathan J. Kotzin, Susan A. Doyle, Pablo Tebas, Scott E. Hensley, Laura F. Su, Kenneth E. Schmader, E. John Wherry	107
17	Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral ?blips? 2005 ·Vaccine ·Rob Roy MacGregor, (unknown), Kenneth E. Ugen, Pablo Tebas, Theresa Higgins, Yaela Baine, Renata Ciccarelli, Richard S. Ginsberg, David M. Weiner	35
18	A Phase II Randomized Study of the Virologic and Immunologic Effect of Zidovudine + Stavudine versus Stavudine Alone and Zidovudine + Lamivudine in Patients with >300 CD4 Cells Who Were Antiretroviral Naive (ACTG 298) 2002 ·AIDS Research and Human Retroviruses ·Richard B. Pollard, Camlin Tierney, Diane V. Havlir, Pablo Tebas, Lawrence Fox, Laura Smeaton, Douglas D. Richman, Gerald Friedland	7
19	Bone abnormalities in HIV-infected patients on HAART 2001 ·Kristin Mondy, Pablo Tebas	3
20	Natural killer cell proliferation and renal disease: A functional and phenotypic study 1996 ·Cytometry ·Juan Antonio Vargas, Juan Gea‐Banacloche, Santiago Ramón y Cajal, (unknown), Pablo Tebas, (unknown), Alberto Durántez	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact